Catalyst Pharmaceuticals Stock Forecast
Catalyst Pharmaceuticals stock price ended on $11.91 on Tuesday after gaining 1.1%
(Updated on Oct 03, 2023)
The Catalyst Pharmaceuticals stock price gained 1.10% on the last trading day (Tuesday, 3rd Oct 2023), rising from $11.78 to $11.91. During the last trading day the stock fluctuated 2.22% from a day low at $11.73 to a day high of $11.99. The price has been going up and down for this period, and there has been a -6.29% loss for the last 2 weeks. Volume fell on the last day by -176 thousand shares and in total, 970 thousand shares were bought and sold for approximately $11.55 million. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days.
Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.
The stock lies in the lower of a wide and falling trend in the short term, and this may normally pose a very good buying opportunity. If the lower trend floor at $11.66 is broken, it will firstly indicate a stronger fall rate. Given the current short-term trend, the stock is expected to fall -6.91% during the next 3 months and, with a 90% probability hold a price between $10.85 and $13.40 at the end of this 3-month period.
CPRX Signals & Forecast
A buy signal was issued from a pivot bottom point on Friday, September 29, 2023, and so far it has risen 1.88%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell during the last trading day despite gaining prices. This causes a divergence between volume and price and it may be an early warning. The stock should be watched closely. Some negative signals were issued as well, and these may have some influence on the near short-term development. The Catalyst Pharmaceuticals stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $11.97 and $13.17. A break-up above any of these levels will issue buy signals.
Support, Risk & Stop-loss for Catalyst Pharmaceuticals stock
Catalyst Pharmaceuticals finds support from accumulated volume at $11.78 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved $0.260 between high and low, or 2.22%. For the last week, the stock has had daily average volatility of 2.85%.
Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.
Trading Expectations (CPRX) For The Upcoming Trading Day Of Wednesday 4th
For the upcoming trading day on Wednesday, 4th we expect Catalyst Pharmaceuticals to open at $11.88, and during the day (based on 14 day Average True Range), to move between $11.52 and $12.30, which gives a possible trading interval of +/-$0.387 (+/-3.25%) up or down from last closing price. If Catalyst Pharmaceuticals takes out the full calculated possible swing range there will be an estimated 6.50% move between the lowest and the highest trading price during the day.
Since the stock is closer to the support from accumulated volume at $11.78 (1.09%) than the resistance at $12.46 (4.62%), our systems sees the trading risk/reward intra-day as attractive and believe profit can be made before the stock reaches first resistance..
Is Catalyst Pharmaceuticals stock A Buy?
Catalyst Pharmaceuticals holds several negative signals and is within a wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.
Current score: -1.740 Open Broker Account
Sell Candidate UnchangedPredicted Opening Price for Catalyst Pharmaceuticals of Wednesday, October 4, 2023
The predicted opening price is based on yesterday's movements between high, low, and closing price.
| Fair opening price October 4, 2023 | Current price |
|---|---|
| $11.88 | $11.91 (Overvalued) |
Remember To Visit Our YouTube Channel
Trading levels for CPRX
Fibonacci Support & Resistance Levels
| Level | Price | |||
|---|---|---|---|---|
| Resistance | R3 | 12.14 | 1.90 % | |
| R2 | 12.04 | 1.07 % | ||
| R1 | 11.98 | 0.554 % | ||
| Current price: | 11.91 | |||
| Support | S1 | 11.78 | -1.11 % | |
| S2 | 11.72 | -1.63 % | ||
| S3 | 11.62 | -2.46 % |
Accumulated Volume Support & Resistance Levels
| Level | Price | |||
|---|---|---|---|---|
| Resistance | R3 | 13.47 | 13.10 % | |
| R2 | 12.81 | 7.56 % | ||
| R1 | 12.46 | 4.62 % | ||
| Current price | 11.91 | |||
| Support | S1 | 11.78 | -1.09% | |
| S2 | 11.69 | -1.85% | ||
| S3 | 0 | . |
FAQ
Click here for our free guide on how to buy Catalyst Pharmaceuticals Stock.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develop... CPRX Profile
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
